Mazdutide: Side Effects & Safety
Part of the Mazdutide Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
Mazdutide's side effect profile is consistent with GLP-1 agonist-class medications, with GI effects predominating. The glucagon component adds theoretical considerations for glucose control and cardiovascular effects that require ongoing monitoring in Phase 3 trials.
Reported Side Effects
- Nausea and vomiting: Most common, consistent with GLP-1 class
- Diarrhea
- Decreased appetite
- Heart rate increase: Mild, consistent with glucagon effects
- Injection site reactions: Mild
Important Limitations
Long-term safety data beyond Phase 3 trial durations is not available. The effects of chronic glucagon receptor activation on hepatic function, cardiac health, and amino acid metabolism require further characterization. Mazdutide is not approved for use in any market.
Potential Contraindications
- Personal/family history of MTC or MEN2 (GLP-1 class warning)
- Severe hepatic or renal impairment
- Pregnancy and breastfeeding